Literature DB >> 6803646

Genetic control of autoimmunity to acetylcholine receptors: role of Ia molecules.

P Christadoss, V A Lennon, C J Krco, E H Lambert, C S David.   

Abstract

Evidence that human susceptibility to myasthenia gravis (MG) might be determined genetically is suggested by clinical surveys showing an association of MG with an increased frequency of certain histocompatibility antigens. We have studied the experimental autoimmune model of MG in mice to investigate whether or not major histocompatibility complex (MHC) gene products play a role in determining susceptibility to EAMG. When MHC congenic and recombinant strains of mice were inoculated with Torpedo acetylcholine receptor (AChR) and adjuvants, the magnitude of autoantibody responses to muscle AChR and of the defect of neuromuscular transmission (i.e., reduction in MEPP amplitude) closely paralleled in vitro lymphocyte proliferative responses to torpedo AChR. Reduction in MEPP amplitude correlated strikingly with the degree to which autologous muscle AChR was complexed with antibody. Lymphocyte responses to Torpedo AChR, antibody responses to mouse muscle AChR, and susceptibility to EAMG are controlled by gene(s) at the I-A subregion of the H-2 complex. Backcross studies confirmed that lymphocyte proliferative responses to AChR are controlled by a Mendelian dominant gene linked to H-2, probably at the I-A subregion. Mutation at the I-A subregion in the B6 strain, which resulted in structural alteration of the Ia molecule, converted high responsiveness to low responsiveness. Lymphocyte responses were eliminated by blocking Ia antigens on lymph node cell surfaces with specific anti-I-A alloantisera. Cellular immune responses to AChR are dependent on Lyt 1+23- cells and adherent cells. These data implicate a macrophage-associated Ia molecular in induction of autoimmune responses to AChR, probably in the presentation of AChR to helper (Lyt 1+23-) T-lymphocytes, which thereby help B-lymphocytes to differentiate into anti-AChR antibody forming cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6803646     DOI: 10.1111/j.1749-6632.1981.tb33737.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Ek alpha transgene in B10 mice suppresses the development of myasthenia gravis.

Authors:  P Christadoss; C S David; M Shenoy; S Keve
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  Progress on studies of myasthenia gravis during 1982.

Authors:  J Lindstrom
Journal:  Surv Immunol Res       Date:  1983

3.  Biochemical evidence for multiple I-E Ia molecules.

Authors:  W P Lafuse; P S Corser; C S David
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

Review 4.  Immunopathology of acetylcholine receptors in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Springer Semin Immunopathol       Date:  1982

Review 5.  Myasthenia gravis--current concepts.

Authors:  C Herrmann; J M Lindstrom; J C Keesey; D G Mulder
Journal:  West J Med       Date:  1985-06

6.  Gastrointestinal hypomotility with loss of enteric nicotinic acetylcholine receptors: active immunization model in mice.

Authors:  J W Meeusen; K E Haselkorn; J P Fryer; T J Kryzer; S J Gibbons; Y Xiao; V A Lennon
Journal:  Neurogastroenterol Motil       Date:  2012-10-17       Impact factor: 3.598

7.  Residues within the alpha subunit sequence 304-322 of muscle acetylcholine receptor forming autoimmune CD4+ epitopes in BALB/c mice.

Authors:  P I Karachunski; N Ostlie; B M Conti-Tronconi; M Bellone
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

8.  Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis.

Authors:  P Christadoss; J M Lindstrom; R W Melvold; N Talal
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.